ImmunityBio (NASDAQ:IBRX) Director Sells $92,500.00 in Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 10,000 shares of the company’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $9.25, for a total value of $92,500.00. Following the completion of the sale, the director owned 3,081,604 shares of the company’s stock, valued at $28,504,837. This trade represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ImmunityBio Trading Up 17.5%

NASDAQ IBRX traded up $1.72 on Tuesday, hitting $11.55. 82,882,982 shares of the company traded hands, compared to its average volume of 31,529,002. The business’s 50 day moving average price is $4.82 and its 200-day moving average price is $3.24. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $12.28. The company has a market capitalization of $11.38 billion, a price-to-earnings ratio of -30.39 and a beta of 0.16.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, sell-side analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

Hedge Funds Weigh In On ImmunityBio

Several large investors have recently modified their holdings of IBRX. Slow Capital Inc. bought a new stake in ImmunityBio in the third quarter worth $25,000. Truist Financial Corp purchased a new stake in shares of ImmunityBio in the third quarter valued at $27,000. Swiss Life Asset Management Ltd bought a new stake in shares of ImmunityBio in the 3rd quarter worth about $27,000. WealthPlan Investment Management LLC purchased a new position in shares of ImmunityBio during the 4th quarter worth about $27,000. Finally, Diversify Advisory Services LLC bought a new position in ImmunityBio during the 2nd quarter valued at about $27,000. Institutional investors own 8.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IBRX. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler raised their price target on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. HC Wainwright boosted their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday. BTIG Research increased their target price on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group lifted their target price on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.60.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.